ARCT
NASDAQ · Biotechnology
Arcturus Therapeutics Holdin
$7.28
+0.39 (+5.66%)
Financial Highlights (FY 2026)
Revenue
92.23M
Net Income
-73,964,644
Gross Margin
—
Profit Margin
-80.2%
Rev Growth
-26.4%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 42.6% | 42.6% |
| Operating Margin | -93.0% | -83.7% | -13.7% | -14.9% |
| Profit Margin | -80.2% | -76.2% | -16.2% | -15.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 92.23M | 125.37M | 31.39M | 23.67M |
| Gross Profit | — | — | 13.39M | 10.09M |
| Operating Income | -85,740,109 | -104,887,995 | -4,296,176 | -3,517,635 |
| Net Income | -73,964,644 | -90,482,777 | -5,088,256 | -3,711,629 |
| Gross Margin | — | — | 42.6% | 42.6% |
| Operating Margin | -93.0% | -83.7% | -13.7% | -14.9% |
| Profit Margin | -80.2% | -76.2% | -16.2% | -15.7% |
| Rev Growth | -26.4% | -26.4% | +5.3% | +9.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 42.41M | 50.91M |
| Total Equity | — | — | 148.93M | 147.38M |
| D/E Ratio | — | — | 0.28 | 0.35 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -82,343,055 | -106,328,533 | -7,015,778 | -5,079,230 |
| Free Cash Flow | — | — | -5,929,972 | -4,352,810 |